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Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-
regulation of p73. 
 
Abstract 
Recent gene expression profiling studies have identified five breast cancer subtypes, of which the 
basal-like subtype is the most aggressive. Basal-like breast cancer poses serious clinical 
challenges as there are currently no targeted therapies available to treat it. Although there is 
increasing evidence that these tumors possess specific sensitivity to cisplatin, its success is often 
compromised due to its dose-limiting nephrotoxicity and the development of drug resistance. To 
overcome this limitation, our goal was to maximize the benefits associated with cisplatin therapy 
through drug combination strategies. Using a validated kinase inhibitor library, we showed that 
inhibition of the mTOR, TGFβRI, NFκB, PI3K/AKT, and MAPK pathways sensitized basal-like 
MDA-MB-468 cells to cisplatin treatment. Further analysis demonstrated that the combination of 
the mTOR inhibitor rapamycin and cisplatin generated significant drug synergism in basal-like 
MDA-MB-468, MDA-MB-231, and HCC1937 cells but not in luminal-like T47D or MCF-7 
cells. We further showed that the synergistic effect of rapamycin plus cisplatin on basal-like 
breast cancer cells was mediated through the induction of p73. Depletion of endogenous p73 in 
basal-like cells abolished these synergistic effects. In conclusion, combination therapy with 
mTOR inhibitors and cisplatin may be a useful therapeutic strategy in the treatment of basal-like 
breast cancers. 
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